|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00000461 |
|
Date of registration:
|
27/10/1999 |
|
Primary sponsor: |
|
|
Public title:
|
Harvard Atherosclerosis Reversibility Project (HARP)
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
December 1986 |
|
Target sample size:
|
|
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00000461 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Primary Purpose: Treatment
|
|
|
Contacts
|
|
Name:
|
Frank Sacks |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Brigham and Women's Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Men and women, normocholesterolemic, with 30 percent or greater narrowing of a coronary
artery lumen as revealed by angiography. (Cholesterol-Lowering Agent Trial).
Men and women with angiographically-documented coronary heart disease (Fish Oil Tr
Age minimum:
18 Years
Age maximum:
75 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Cardiovascular Diseases
|
|
Coronary Disease
|
|
Heart Diseases
|
|
Myocardial Ischemia
|
|
Intervention(s)
|
|
Drug: cholestyramine
|
|
Drug: fatty acids, omega-3
|
|
Drug: gemfibrozil
|
|
Drug: niacin
|
|
Drug: pravastatin
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|